
The presentation of Zealand Pharma’s financial results for the first half and second quarter of 2017 did not bring many surprises.
The company had already announced its royalty income from partner Sanofi prior to the publication of the report, and both revenue and net loss came in largely as expected.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app